의약품 CDMO 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 제품별, 서비스별, 워크플로우별, 치료 분야별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Pharmaceutical Contract Development And Manufacturing Organization Market Summary

The global pharmaceutical contract development and manufacturing organization market size was estimated at USD 155.5 billion in 2024 and is projected to reach USD 293.6 billion by 2033, growing at a CAGR of 7.38% from 2025 to 2033. Growth in the market can be attributed to the rising investments by CDMOs to expand new drug development and the increasing demand for novel therapies.

In addition, growing investments in pharmaceutical R&D, rising demand for genetic drugs, and growing prevalence of cancer & age-related disorders, coupled with increasing need for advanced therapeutics, are some of the key factors driving market growth.

The pharmaceutical industry is experiencing a significant shift from traditional small molecules to biopharmaceuticals. This includes monoclonal antibodies, vaccines, recombinant proteins, and other therapies such as mRNA treatments. In addition, this shift is driven by the growing prevalence of chronic diseases, an aging global population, and the increasing access to targeted therapies that tend to provide better efficacy and fewer side effects than conventional treatments.

According to the data published by IQVIA in January 2024, the global medicine spending at list prices is anticipated to rise by 38% between 2024 and 2028, with biologics accounting for more than 40% of that growth, reflecting the central role in the treatments. Regulators such as the U.S. FDA continue to clear record numbers of innovative biologics, approving 50 novel drugs in 2024, of which a significant proportion were advanced biologics and specialty medicines, supported by a 74% first-cycle approval rate that accelerates patient access. Also, biopharmaceuticals represent over half of the late-stage pipeline, and categories such as GLP-1 agonists for diabetes and obesity, cell and gene therapies for rare diseases, and monoclonal antibody-based cancer therapies are shaping demand trajectories. Therefore, CDMOs play an essential role in this environment as biologics production requires complex infrastructure, such as single-use bioreactors, continuous bioprocessing systems, and high-level cold chain logistics, all of which demand expertise and heavy capital investment.

Global Pharmaceutical Contract Development And Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmaceutical contract development and manufacturing organization market report based on type, product, service, workflow, therapeutic area, end use, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecule
  • Branded
  • Generic
• Large Molecule
  • Biologics
  • Biosimilar
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• API
  • Traditional Active Pharmaceutical Ingredient (Traditional API)
  • Highly Potent Active Pharmaceutical Ingredient (HP-API)
  • Biologics
  • Others
• Drug Product
  • Oral solid dose
  • Semi-solid dose
  • Liquid dose
  • Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
  • Pre-formulation & Formulation Development Services
  • Process Development & Optimization
  • Analytical Testing & Method Validation
  • Scale-up & Tech Transfer
• Contract Manufacturing
  • API Manufacturing
  • Finished Drug Products Manufacturing
• Packaging and Labelling
• Regulatory Affairs
• Others
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical
• Commercial
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disease
• Metabolic Disorders
• Autoimmune Diseases
• Respiratory Diseases
• Ophthalmology
• Gastrointestinal Disorders
• Orthopedic Diseases
• Dental Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Small Pharmaceutical Companies
• Medium Pharmaceutical Companies
• Large Pharmaceutical Companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Product
  • 1.2.3. Services
  • 1.2.4. Workflow
  • 1.2.5. Therapeutic Area
  • 1.2.6. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Consumption of Biopharmaceuticals
    • 3.2.1.2. Increasing Demand for One-Stop-Shop CDMOS
    • 3.2.1.3. Rising Demand for Advanced Therapeutics
    • 3.2.1.4. Increasing Outsourcing Services by Pharmaceutical Companies
    • 3.2.1.5. Upsurge in the Number Of Clinical Trials
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios Within Developing Countries
  • 3.2.3. Market Opportunity Analysis
• 3.3. R&D Spending Analysis
  • 3.3.1. Venture Capital & Government Funding Scenario
• 3.4. Industry Ecosystem Analysis
  • 3.4.1. Demand Analysis
  • 3.4.2. Supply Chain Analysis
• 3.5. Technology Landscape
• 3.6. Clinical Trial Volume Analysis, 2024
• 3.7. Pricing Analysis
• 3.8. Tariff and Trade Agreement Impact Analysis
• 3.9. Value Chain Analysis
  • 3.9.1. Supply Trends
  • 3.9.2. Demand Trends
• 3.10. Market Analysis Tools
  • 3.10.1. Porter's Five Force Analysis
  • 3.10.2. PESTEL by SWOT Analysis

Chapter 4. Pharmaceutical Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis

• 4.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
• 4.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
• 4.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
• 4.4. Small Molecule
  • 4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Branded
    • 4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Generic
    • 4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Large Molecule
  • 4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Biologics
    • 4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Biosimilar
    • 4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis

• 5.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
• 5.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
• 5.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 5.4. API
  • 5.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
    • 5.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
    • 5.4.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Biologics
    • 5.4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Others
    • 5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Drug Product
  • 5.5.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Oral Solid Dose
    • 5.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Semi-Solid Dose
    • 5.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Liquid Dose
    • 5.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Pharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis

• 6.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
• 6.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
• 6.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 6.4. Contract Development
  • 6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Pre-formulation & Formulation Development Services
    • 6.4.2.1. Pre-formulation & Formulation Development Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Process Development & Optimization
    • 6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Analytical Testing & Method Validation
    • 6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Scale-up & Tech Transfer
    • 6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Contract Manufacturing
  • 6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. API Manufacturing
    • 6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Finished Drug Products Manufacturing
    • 6.5.3.1. Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Packaging and Labelling
  • 6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Regulatory Affairs
  • 6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis

• 7.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
• 7.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
• 7.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
• 7.4. Clinical
  • 7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Commercial
  • 7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis

• 8.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
• 8.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
• 8.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
• 8.4. Oncology
  • 8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Infectious Diseases
  • 8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Neurological Disorders
  • 8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Cardiovascular Diseases
  • 8.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Metabolic Disorders
  • 8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.9. Autoimmune Diseases
  • 8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.10. Respiratory Diseases
  • 8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.11. Ophthalmology
  • 8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.12. Gastrointestinal Disorders
  • 8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.13. Orthopedic Diseases
  • 8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.14. Dental Diseases
  • 8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.15. Others
  • 8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Pharmaceutical Contract Development and Manufacturing Organization Market: End-Use Estimates & Trend Analysis

• 9.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By End-Use: Segment Dashboard
• 9.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By End-Use: Movement Analysis
• 9.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End-Use, 2021 - 2033 (USD Million)
• 9.4. Small Pharmaceutical Companies
  • 9.4.1. Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Medium Pharmaceutical Companies
  • 9.5.1. Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Large Pharmaceutical Companies
  • 9.6.1. Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Pharmaceutical Contract Development And Manufacturing Organization Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Dashboard
• 10.2. Regional Market Share Analysis, 2024 & 2033
• 10.3. North America
  • 10.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.3.2. U.S
    • 10.3.2.1. Key Country Dynamics
    • 10.3.2.2. Competitive Scenario
    • 10.3.2.3. Regulatory Framework
    • 10.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.3.3. Canada
    • 10.3.3.1. Key Country Dynamics
    • 10.3.3.2. Competitive Scenario
    • 10.3.3.3. Regulatory Framework
    • 10.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.3.4. Mexico
    • 10.3.4.1. Key Country Dynamics
    • 10.3.4.2. Competitive Scenario
    • 10.3.4.3. Regulatory Framework
    • 10.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.4. Europe
  • 10.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.2. UK
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Competitive Scenario
    • 10.4.2.3. Regulatory Framework
    • 10.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.3. Germany
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Competitive Scenario
    • 10.4.3.3. Regulatory Framework
    • 10.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.4. France
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Competitive Scenario
    • 10.4.4.3. Regulatory Framework
    • 10.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.5. Italy
    • 10.4.5.1. Key Country Dynamics
    • 10.4.5.2. Competitive Scenario
    • 10.4.5.3. Regulatory Framework
    • 10.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.6. Spain
    • 10.4.6.1. Key Country Dynamics
    • 10.4.6.2. Competitive Scenario
    • 10.4.6.3. Regulatory Framework
    • 10.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.7. Denmark
    • 10.4.7.1. Key Country Dynamics
    • 10.4.7.2. Competitive Scenario
    • 10.4.7.3. Regulatory Framework
    • 10.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.8. Sweden
    • 10.4.8.1. Key Country Dynamics
    • 10.4.8.2. Competitive Scenario
    • 10.4.8.3. Regulatory Framework
    • 10.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.9. Norway
    • 10.4.9.1. Key Country Dynamics
    • 10.4.9.2. Competitive Scenario
    • 10.4.9.3. Regulatory Framework
    • 10.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.2. China
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Competitive Scenario
    • 10.5.2.3. Regulatory Framework
    • 10.5.2.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.3. India
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Competitive Scenario
    • 10.5.3.3. Regulatory Framework
    • 10.5.3.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.4. Japan
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Competitive Scenario
    • 10.5.4.3. Regulatory Framework
    • 10.5.4.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.5. Australia
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Competitive Scenario
    • 10.5.5.3. Regulatory Framework
    • 10.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.6. South Korea
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Competitive Scenario
    • 10.5.6.3. Regulatory Framework
    • 10.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.7. Thailand
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Competitive Scenario
    • 10.5.7.3. Regulatory Framework
    • 10.5.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.6. Latin America
  • 10.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.2. Brazil
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Competitive Scenario
    • 10.6.2.3. Regulatory Framework
    • 10.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.6.3. Argentina
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Competitive Scenario
    • 10.6.3.3. Regulatory Framework
    • 10.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.7. MEA
  • 10.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.2. South Africa
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Competitive Scenario
    • 10.7.2.3. Regulatory Framework
    • 10.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.3. UAE
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Competitive Scenario
    • 10.7.3.3. Regulatory Framework
    • 10.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.4. Saudi Arabia
    • 10.7.4.1. Key Country Dynamics
    • 10.7.4.2. Competitive Scenario
    • 10.7.4.3. Regulatory Framework
    • 10.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.5. Kuwait
    • 10.7.5.1. Key Country Dynamics
    • 10.7.5.2. Competitive Scenario
    • 10.7.5.3. Regulatory Framework
    • 10.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.6. Qatar
    • 10.7.6.1. Key Country Dynamics
    • 10.7.6.2. Competitive Scenario
    • 10.7.6.3. Regulatory Framework
    • 10.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.7.7. Oman
    • 10.7.7.1. Key Country Dynamics
    • 10.7.7.2. Competitive Scenario
    • 10.7.7.3. Regulatory Framework
    • 10.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Key Participant Categorization
  • 11.1.1. Market Leaders
  • 11.1.2. Emerging Players
• 11.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 11.3. Company Profiles
  • 11.3.1. Thermo Fisher Scientific, Inc
    • 11.3.1.1. Company Overview
    • 11.3.1.2. Financial Performance
    • 11.3.1.3. Service Benchmarking
    • 11.3.1.4. Strategic Initiatives
  • 11.3.2. Lonza
    • 11.3.2.1. Company Overview
    • 11.3.2.2. Financial Performance
    • 11.3.2.3. Service Benchmarking
    • 11.3.2.4. Strategic Initiatives
  • 11.3.3. Recipharm AB
    • 11.3.3.1. Company Overview
    • 11.3.3.2. Financial Performance
    • 11.3.3.3. Service Benchmarking
    • 11.3.3.4. Strategic Initiatives
  • 11.3.4. Catalent, Inc
    • 11.3.4.1. Company Overview
    • 11.3.4.2. Financial Performance
    • 11.3.4.3. Service Benchmarking
    • 11.3.4.4. Strategic Initiatives
  • 11.3.5. WuXi AppTec, Inc
    • 11.3.5.1. Company Overview
    • 11.3.5.2. Financial Performance
    • 11.3.5.3. Service Benchmarking
    • 11.3.5.4. Strategic Initiatives
  • 11.3.6. Samsung Biologics
    • 11.3.6.1. Company Overview
    • 11.3.6.2. Financial Performance
    • 11.3.6.3. Service Benchmarking
    • 11.3.6.4. Strategic Initiatives
  • 11.3.7. Piramal Pharma Solutions
    • 11.3.7.1. Company Overview
    • 11.3.7.2. Financial Performance
    • 11.3.7.3. Service Benchmarking
    • 11.3.7.4. Strategic Initiatives
  • 11.3.8. Siegfried Holding AG
    • 11.3.8.1. Company Overview
    • 11.3.8.2. Financial Performance
    • 11.3.8.3. Service Benchmarking
    • 11.3.8.4. Strategic Initiatives
  • 11.3.9. Corden Pharma International
    • 11.3.9.1. Company Overview
    • 11.3.9.2. Financial Performance
    • 11.3.9.3. Service Benchmarking
    • 11.3.9.4. Strategic Initiatives
  • 11.3.10. Cambrex Corporation
    • 11.3.10.1. Company Overview
    • 11.3.10.2. Financial Performance
    • 11.3.10.3. Service Benchmarking
    • 11.3.10.4. Strategic Initiatives
  • 11.3.11. Delpharm
    • 11.3.11.1. Company Overview
    • 11.3.11.2. Financial Performance
    • 11.3.11.3. Service Benchmarking
    • 11.3.11.4. Strategic Initiatives
  • 11.3.12. Jubilant Pharmova / HollisterStier
    • 11.3.12.1. Company Overview
    • 11.3.12.2. Financial Performance
    • 11.3.12.3. Service Benchmarking
    • 11.3.12.4. Strategic Initiatives
  • 11.3.13. Eurofins CDMO
    • 11.3.13.1. Company Overview
    • 11.3.13.2. Financial Performance
    • 11.3.13.3. Service Benchmarking
    • 11.3.13.4. Strategic Initiatives
  • 11.3.14. Almac Pharma Services
    • 11.3.14.1. Company Overview
    • 11.3.14.2. Financial Performance
    • 11.3.14.3. Service Benchmarking
    • 11.3.14.4. Strategic Initiatives